A Minimal-Risk, Multi-Center, Prospective, Clinical Trial to Evaluate the PrevisEA Device for Predicting Gastrointestinal Impairment
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Gastrointestinal Complication
- Sponsor
- Entac Medical Inc.
- Enrollment
- 400
- Locations
- 8
- Primary Endpoint
- Performance of the PrevisEA device
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postoperative bowel obstruction. GII is defined as failure of successful early oral re-feeding in a subject undergoing major abdominal surgery. For subjects who are allowed to resume a diet during the first 24 hours after surgery, a failure to successfully orally re-feed a subject is defined as presentation with emesis, requiring a reversal of diet, or the placement of a nasogastric tube on first postoperative day or later.
The device is considered non-significant risk (NSR). The device does not inform medical decisions in this study. Researchers will be blinded to results of the device during this study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 and ≤ 90 years
- •Patient undergoing elective intestinal resection surgery including open, laparoscopic, robotic, or hand-assist technique for:
- •Segmental ileocolic resection with or without diversion
- •Segmental colon resection with or without diversion
- •Segmental coloproctectomy with or without diversion
- •Low anterior resection with or without diversion
- •Abdominoperineal resection
- •Total abdominal colectomy with or without diversion
- •Proctocolectomy with or without end ileostomy or diversion
- •Closure of end colostomy (Hartmann's reversal)
Exclusion Criteria
- •Allergies to any of the device components (i.e., adhesive)
- •Inability to have prototype device applied to their abdominal wall due to disease conditions or surgical alterations(e.g., fistulas, stomas, drains, etc.)
- •Patients undergoing:
- •Small bowel resection without colonic resection
- •Transanal proctectomy without transabdominal approach
- •Perineal proctosigmoidectomy
- •Closure of loop colostomy or ileostomy
- •Patients with preoperative evidence of an anastomotic leak, deep wound infection, organ space infection, or urinary tract infection
Outcomes
Primary Outcomes
Performance of the PrevisEA device
Time Frame: 1-14 days
The performance (accuracy) of the device in predicting development of GII will be assessed through evaluation of the primary outcome measures of sensitivity and specificity for the device.
Secondary Outcomes
- Positive predictive value (PPV)(1-14 days)
- Overall percent agreement (OPA)(1-14 days)
- Negative predictive value (NPV)(1-14 days)